News
Stocktwits on MSN1d
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...
Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...
Asianet Newsable on MSN2d
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic
Insmed shares surged after U.S. regulators approved Brinsupri, the first treatment for non-cystic fibrosis bronchiectasis.
Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...
After Insmed (INSM) announced the FDA approved brensocatib as “Brinsupri,” making it the first approved treatment for non-cystic fibrosis ...
Hosted on MSN2d
Insmed price target raised to $138 from $120 at RBC Capital
After Insmed (INSM) announced the FDA approved Brinsupri for non-cystic fibrosis bronchiectasis, RBC Capital raised the firm’s price target on Insmed to $138 from $120 and keeps an Outperform ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback